Zomedica (NYSEAMERICAN:ZOM) Announces Earnings Results

Zomedica (NYSEAMERICAN:ZOM – Get Rating) announced its earnings results on Wednesday. The company reported ($0.01) earnings per share (EPS) for the quarter, Yahoo Finance reports. Zomedica had a negative net margin of 104.92% and a negative return on equity of 6.51%. The firm had revenue of $6.16 million during the quarter, compared to analyst estimates of $6.20 million.

Zomedica Price Performance

ZOM stock opened at $0.23 on Friday. Zomedica has a 1-year low of $0.15 and a 1-year high of $0.41.

Institutional Trading of Zomedica

Several institutional investors have recently added to or reduced their stakes in ZOM. Renaissance Technologies LLC bought a new stake in Zomedica in the 2nd quarter valued at $552,000. Vanguard Group Inc. boosted its stake in Zomedica by 5.1% in the 3rd quarter. Vanguard Group Inc. now owns 46,329,005 shares of the company’s stock valued at $9,775,000 after purchasing an additional 2,252,651 shares during the period. Jane Street Group LLC boosted its stake in Zomedica by 413.9% in the 2nd quarter. Jane Street Group LLC now owns 1,082,261 shares of the company’s stock valued at $238,000 after purchasing an additional 871,646 shares during the period. BlackRock Inc. boosted its stake in Zomedica by 5.6% in the 1st quarter. BlackRock Inc. now owns 13,418,299 shares of the company’s stock valued at $4,523,000 after purchasing an additional 707,993 shares during the period. Finally, Millennium Management LLC boosted its stake in Zomedica by 240.8% in the 2nd quarter. Millennium Management LLC now owns 557,672 shares of the company’s stock valued at $123,000 after purchasing an additional 394,058 shares during the period. 9.42% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Separately, Dawson James initiated coverage on Zomedica in a research report on Friday, January 6th. They set a “buy” rating and a $6.00 price target on the stock.

About Zomedica

(Get Rating)

Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company engages in the development and commercialization of TRUFORMA platform, which offers point-of-care diagnostic products for disease states in dogs and cats; and PulseVet, provides for treatment of various musculoskeletal issues, such as broken bones, tendonitis, and torn ligaments in horses and small animals.